Amylyx Pharmaceuticals, Inc. (AMLX) › Operating IncomeAmylyx Pharmaceuticals, Inc. (AMLX) — Operating IncomeAnnual figures by period end, from SEC filings.2021-12-31: -$82.69M2022-12-31: -$201.34M2023-12-31: $38.80M2024-12-31: -$314.73M2025-12-31: -$153.29M-$153.29M2021-12-31Operating Income (USD)2025-12-31Period endedOperating IncomeChange YoYSource filing2025-12-31-$153.29M—2026-03-03From 2025-01-012024-12-31-$314.73M-911.1%2026-03-03From 2024-01-012023-12-31$38.80M—2025-03-04From 2023-01-012022-12-31-$201.34M—2024-02-22From 2022-01-012021-12-31-$82.69M—2024-02-22From 2021-01-01Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)